EndpointsMay 131 min read

Abeona shifts from eye gene therapy to solid tumor T‑cell programs as AstraZeneca’s rare disease drug clears Phase 3

May 13, 2026read at Endpoints ↗Positive readoutPositive

Abeona Therapeutics announced it is ending its eye‑focused gene‑therapy projects and will redirect resources toward developing T‑cell based treatments for solid tumors.

The company says the pivot reflects a strategic move to pursue oncology opportunities after encountering hurdles in the ophthalmology space.

In parallel, AstraZeneca reported that its experimental drug for a rare disease achieved its primary endpoints in a Phase 3 trial, marking a significant milestone for the program.

The positive readout positions AstraZeneca to begin discussions with regulators and could lead to a future market launch, offering new options for patients with the condition.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3”

read at Endpoints ↗

81 words · retrieved May 13

sharex / twitter linkedin

Abeona shifts from eye gene therapy to solid tumor T‑cell programs as AstraZeneca’s rare disease drug clears Phase 3

comments(0)

Abeona shifts from eye gene therapy to solid tumor T‑cell programs as AstraZeneca’s rare disease drug clears Phase 3

comments(0)

Abeona shifts from eye gene therapy to solid tumor T‑cell programs as AstraZeneca’s rare disease drug clears Phase 3

comments(0)

Abeona shifts from eye gene therapy to solid tumor T‑cell programs as AstraZeneca’s rare disease drug clears Phase 3

comments(0)

Abeona shifts from eye gene therapy to solid tumor T‑cell programs as AstraZeneca’s rare disease drug clears Phase 3

Abeona shifts from eye gene therapy to solid tumor T‑cell programs as AstraZeneca’s rare disease drug clears Phase 3